Atyr Pharma, Inc.

Pangu Biopharma Limited

Applied Molecular Evolution

Prometheus Biosciences, Inc.

Cell Matrix, Inc.

Cedars-sinai Medical Center

Medimmune Limited

Ixsys, Incorporated

Other

Eli Lilly and Company

Velosbio Inc.

University of Nebraska

Pangn Biopharma Limited

Applied Molecule Evolution, Inc.

Dr. Falk Pharma Gmbh

Jeffry Dean Watkins

Alain Philippe Vasserot

Kyle P Chiang

John D Mendlein

Leslie Ann Greene

Fei Hong

Cheryl L Quinn

Wing-Sze Lo

William D Huse

Ying Tang

Kristi Helen Piehl

Herren Wu

Julian Davies

Wei Zhang

Peter C Brooks

Ying Buechler

Ryan Andrew Adams

Chi-Fang Wu

Stephan R Targan

Leslie Sydnor Johnson

David Matthew Marquis

James F Young

Zhiwen Xu

Jirong Lu

Brian Lannutti

Craig Duane Dickinson

Barrett Allan

James David Pancook

Scott Koenig

Janine M Bilsborough

Anthony W Siadak

Alejandro A Aruffo

Jurgen Bajorath

Diane Hollenbaugh

Bryan Edward Jones

Catherine Brautigam Beidler

Peter Edward Vaillancourt

Darin Lee

Minh-Ha Do

Cindy T Dickerson

Daniel Broek

Marc Thomas

Alina He

Janine Bilsborough

Barbara A Thorne

Lihua Huang

Bradley Henkle

Patricia McNeeley

Jennifer Lynne Reed

Thanh-Trang Vo

Rafael Rojas

Matthew Reissman

J Monty Watkins

Rajesh Belani

Dermot P Mcgovern

Linda Harris

Scott William Rowlinson

Katti Jessen

Barrett W Allan

Karen K Berry

Oksana Lockridge

Alka Potdar

Weidong Jiang

Alain Phillippe Vasserot

Brian Ondek

Alian P Vasserot

Kristi Piehl

Provided herein are immunoconjugates comprising an anti-ROR-1 antibody or an antigen-fragmentfragmentthereof and a drug moiety. These immunoconjugates are useful for treating ROR-1 expressing cancers.

ROR1 antibody immunoconjugates

Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohns disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.

Methods and systems for selection and treatment of patients with inflammatory diseases

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof

Optimized anti-TL1A antibodies

The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.

Histidyl-tRNA synthetase-Fc conjugates

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Cysteinyl-tRNA synthetase

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Histidyl-tRNA synthetases

Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl tRNA synthetases

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases

Provided herein are immunoconjugates comprising an anti-ROR1 antibody or an antigen-fragment fragment thereof and a drug moiety. These immunoconjugates are useful for treating ROR1 expressing cancers.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases

Growing community of inventors

Encinitas, CA, United States of America

Jeffry Dean Watkins